TickerFiles

BioXcel Therapeutics, Inc. 10-Q filing

Filed 2025-08-12 · Report date 2025-06-30 · 2025

View Original SEC Filing

Filing metadata

Accession number
0001558370-25-011158
Form type
10-Q
CIK
0001720893
Primary document
https://www.sec.gov/Archives/edgar/data/1720893/000155837025011158/btai-20250630x10q.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for BioXcel Therapeutics, Inc..

Reported financial metrics

MetricCurrentPriorChange
Revenue$288,000--
Cost Of Revenue$121,000--
Operating Income$-26.0M--
Net Income$-26.4M--
Eps Basic-4.17--
Eps Diluted-4.17--
Cash And Equivalents$17.4M--
Total Assets$25.8M--
Total Liabilities$133.5M--
Shareholders Equity$-107.7M--
Operating Cash Flow$-24.6M--
Capital Expenditures$0--